Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.64 |
| ▸ | MME | P08473 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.38 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL627910 | 1.00 | TGFBR1 (0.64) | TGFBR1MMEKDM4EMAPTTHRB | |
| SCHEMBL3448069 | 1.00 | TGFBR1 (0.64) | TGFBR1MMEKDM4EMAPTTHRB | |
| Biphenyl SCHEMBL27871860 | 0.87 | TGFBR1 (0.51) | TGFBR1MMETHRBCA2CA1 | |
| SCHEMBL627951 | 0.83 | TGFBR1 (0.46) | TGFBR1MMEKDM4EMAPTTHRB | |
| SCHEMBL627952 | 0.83 | TGFBR1 (0.46) | TGFBR1MMEKDM4EMAPTTHRB | |
| SCHEMBL193660 | 0.82 | TGFBR1 (0.44) | TGFBR1MMEKDM4EMAPTTHRB | |
| SCHEMBL18506232 | 0.82 | TGFBR1 (0.44) | TGFBR1MMEKDM4EMAPTTHRB | |
| SCHEMBL193659 | 0.82 | TGFBR1 (0.44) | TGFBR1MMEKDM4EMAPTTHRB | |
| SCHEMBL12661081 | 0.82 | TGFBR1 (0.44) | TGFBR1MMEMAPTTHRBALOX15 | |
| SCHEMBL7036756 | 0.82 | TGFBR1 (0.44) | TGFBR1MMETHRBSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112898219-A | Preparation process of amino acid N-carboxylic anhydride | 荆楚理工学院 | 2021-06-04 | — | — | CN | disclosed |
| US-9278922-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278922-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278922-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-03-08 | — | — | US | disclosed |
| EP-2419404-B1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC (US) | 2015-11-04 | — | — | EP | disclosed |
| CN-102459165-B | Antiviral compound | ABBVIE (US) | 2015-09-02 | — | — | CN | disclosed |
| EP-2419404-A1 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2012-02-22 | — | — | EP | disclosed |
| WO-2011154871-A1 | HEPATITIS C VIRUS INHIBITORS | PFIZER LIMITED (GB) | 2011-12-15 | — | — | WO | disclosed |
| WO-2011154871-A1 | HEPATITIS C VIRUS INHIBITORS | PFIZER LIMITED (GB) | 2011-12-15 | — | — | WO | disclosed |
| WO-2010120935-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010120935-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2010-10-21 | — | — | WO | disclosed |
| US-20100267634-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267634-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267634-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100215618-A1 | NOVEL COMPOUNDS - 644 | ARROW THERAPEUTICS LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| US-20100215618-A1 | NOVEL COMPOUNDS - 644 | ARROW THERAPEUTICS LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| US-20100215618-A1 | NOVEL COMPOUNDS - 644 | ARROW THERAPEUTICS LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| US-5523463-A | Method of producing halogenated and alpha-aminoalchohols | HOFFMANN-LA ROCHE INC. (US) | 1996-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100215618-A1 | NOVEL COMPOUNDS - 644 | NR1H4, HAVCR2, CYP3A4 | TGFBR1 567/4885MME 2049/4885KDM4E 1485/4885 |
| US-20100267634-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | TGFBR1 4637/4885MME 131/4885KDM4E 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.